Lee Seung Duk, Han Ho-Seong, Cho Jai Young, Yoon Yoo-Seok, Hwang Dae Wook, Jung Kyuwhan, Yoon Chang Jin, Kwon Yujin, Kim Ji Hoon
Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea.
J Korean Surg Soc. 2012 Jul;83(1):36-42. doi: 10.4174/jkss.2012.83.1.36. Epub 2012 Jun 26.
Radiofrequency ablation (RFA) is an accepted treatment option for primary and metastatic liver tumors. As percutaneous RFA has some limitations, laparoscopic RFA (LRFA) has been used as a therapeutic alternative for the treatment of hepatic malignancies.
Between March 2006 and September 2009, thirty patients with hepatic malignancies that were contraindicated for resection or percutaneous RFA underwent LRFA. Indications for this procedure were hepatocellular carcinoma (HCC, 21 patients), metastatic liver tumor (8 patients) and intrahepatic cholangiocarcinoma (1 patient).
Among the 30 patients who underwent LRFA, 5 patients underwent concomitant laparoscopic liver resection. Intraoperative laparoscopic ultrasound detected new malignant lesions in 4 patients (13.3%). A total of 46 lesions were ablated by LRFA. There was no postoperative mortality. The three-year overall survival rate was 83.7% for the HCC group and 64.3% for the metastatic group.
LRFA for hepatic malignancies proved to be a safe and effective treatment. Also, this procedure is indicated for lesions that are not amenable to percutaneous RFA or liver resection.
射频消融（RFA）是原发性和转移性肝肿瘤公认的治疗选择。由于经皮RFA存在一些局限性，腹腔镜RFA（LRFA）已被用作治疗肝恶性肿瘤的替代疗法。
2006年3月至2009年9月期间，30例因肝恶性肿瘤而禁忌行切除术或经皮RFA的患者接受了LRFA治疗。该手术的适应证包括肝细胞癌（HCC，21例）、肝转移瘤（8例）和肝内胆管癌（1例）。
在接受LRFA治疗的30例患者中，5例同时接受了腹腔镜肝切除术。术中腹腔镜超声在4例患者（13.3%）中检测到新的恶性病变。LRFA共消融了46个病灶。无术后死亡病例。HCC组的三年总生存率为83.7%，转移组为64.3%。
LRFA治疗肝恶性肿瘤被证明是一种安全有效的治疗方法。此外，该手术适用于不适于经皮RFA或肝切除术的病灶。
